Travere Therapeutics is positioned for upside as FILSPARI sales accelerate and the critical FSGS PDUFA decision approaches in April. Read more on TVTX stock here.
Travere Therapeutics Inc. (NASDAQ:TVTX) is one of the best stocks for beginners with little money in 2026. On February 19, ...
Travere Therapeutics (TVTX) is back in focus after Q4 2025 results topped earnings expectations, supported by record demand for FILSPARI, with investors also weighing recent FDA approvals and late ...
15h
Your Kidneys Count: American Kidney Fund Urges Americans to Protect Their Health this Kidney Month
The Kidneys Count campaign provides educational content and resources to help people understand the importance of kidney health and of prevention, early detection and management of kidney disease.
In an effort to battle against what members feel is an existential threat to their business, a group of 10 domestic biotech companies have launched the Midsized Biotech Alliance of America with a ...
For 4Q2025, Nomura Small Cap Core Institutional Class shares gained although the Fund underperformed its Russell 2000 Index ...
Detailed price information for Praxis Precision Medicines Inc (PRAX-Q) from The Globe and Mail including charting and trades.
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and twelve months ended ...
Mirum Pharmaceuticals MIRM reported a loss of 11 cents per share in fourth-quarter 2025, against the Zacks Consensus Estimate ...
Synthekine Inc., an engineered cytokine therapeutics company, today announced the appointment of John A. Orwin as Chair of its Board of Directors. Mr. Orwin succeeds Srinivas Akkaraju, M.D., Ph.D., ...
NORD Calls on Nation to "Show Your Stripes®" on Global Rare Disease Day®, Feb. 28NORWELL, Mass., Feb. 23, 2026 /PRNewswire/ - ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results